Piedmont Cancer Institute

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 160 papers

  • Research Article

Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial

  • Feb 17, 2026
  • Clinical Cancer Research
  • T Kulkarni +14
  • Research Article
  • Citations6

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

  • Feb 01, 2026
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • E L Mayer +24
  • Research Article

Exploration of familial genetic test result communication among Black women within an academic safety net hospital.

  • Jan 30, 2026
  • Familial cancer
  • Ruchi Aluwalia +5
  • Research Article

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

  • Nov 03, 2025
  • Blood
  • Shree Allada +4
  • Research Article
  • Citations2

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

  • Nov 03, 2025
  • Blood
  • Zulfa Omer +24
  • Open Access
  • Research Article

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

  • Nov 03, 2025
  • Blood
  • Evan Chen +24
  • Open Access
  • Research Article

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

  • Nov 03, 2025
  • Blood
  • Kayla Mchugh +14
  • Open Access
  • Research Article
  • Citations5

CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.

  • Sep 15, 2025
  • Neuro-oncology
  • Mackenzie Price +5
  • Research Article
  • Citations1

1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC

  • Sep 01, 2025
  • Annals of Oncology
  • E Arriola Aperribay +16
  • Open Access
  • Research Article
  • Citations2

Performance Drift in a Nationally Deployed Population Health Risk Algorithm in the US Veterans Health Administration

  • Aug 15, 2025
  • JAMA Health Forum
  • Likhitha Kolla +9
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.